SARS-CoV-2 Antibody Neutralization Assay Platforms Based on Epitopes Sources: Live Virus, Pseudovirus, and Recombinant S Glycoprotein RBD

키워드

참고문헌 (96)

1. Wang X, "Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China", Eur Respir J, 55, pp.2000544~ (2020)
2. "COVID-19 coronavirus pandemic"[URL]
3. Acter T, "Evolution of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)as coronavirus disease 2019(COVID-19)pandemic : a global health emergency", Sci Total Environ, 730, pp.138996~ (2020)
4. Zhong NS, "Epidemiology and cause of severe acute respiratory syndrome(SARS)in Guangdong, People’s Republic of China, in February, 2003", Lancet, 362, pp.1353~1358 (2003)
5. Zu ZY, "Coronavirus disease 2019(COVID-19) : a perspective from China", Radiology, 296, pp.E15~E25 (2020)
6. "Naming the coronavirus disease (COVID-19) and the virus that causes it"[URL]
7. Zhao J, "Cell morphological analysis of SARS-CoV-2 infection by transmission electron microscopy", J Thorac Dis, 12, pp.4368~4373 (2020)
8. Walls AC, "Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein", Cell, 181, pp.281~292.e6 (2020)
9. Wu A, "Genome composition and divergence of the novel coronavirus(2019-nCoV)originating in China", Cell Host Microbe, 27, pp.325~328 (2020)
10. Meo SA, "Novel coronavirus 2019-nCoV : prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV", Eur Rev Med Pharmacol Sci, 24, pp.2012~2019 (2020)
11. Zhu N, "A novel coronavirus from patients with pneumonia in China, 2019", N Engl J Med, 382, pp.727~733 (2020)
12. Chen Z, "Genomic and evolutionary comparison between SARS-CoV-2 and other human coronaviruses", J Virol Methods, 289, pp.114032~ (2021)
13. Kumar S, "Coronavirus Disease 2019 (COVID-19). Medical Virology: From Pathogenesis to Disease Control", pp.23~31 (2020), Springer
14. Zumla A, "Coronaviruses-drug discovery and therapeutic options", Nat Rev Drug Discov, 15, pp.327~347 (2016)
15. V’kovski P, "Coronavirus biology and replication : implications for SARS-CoV-2", Nat Rev Microbiol, 19, pp.155~170 (2021)
16. Murgolo N, "SARS-CoV-2 tropism, entry, replication, and propagation : Considerations for drug discovery and development", PLoS Pathog, 17, pp.e1009225~ (2021)
17. Mariano G, "Structural Characterization of SARS-CoV-2 : where we are, and where we need to be", Front Mol Biosci, 7, pp.605236~ (2020)
18. Brahim Belhaouari D, "The strengths of scanning electron microscopy in deciphering SARS-CoV-2 infectious cycle", Front Microbiol, 11, pp.2014~ (2020)
19. Yan R, "Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2", Science, 367, pp.1444~1448 (2020)
20. Huang Y, "Structural and functional properties of SARS-CoV-2 spike protein : potential antivirus drug development for COVID-19", Acta Pharmacol Sin, 41, pp.1141~1149 (2020)
21. Zamorano Cuervo N, "ACE2 : evidence of role as entry receptor for SARS-CoV-2 and implications in comorbidities", eLife, 9, pp.e61390~ (2020)
22. Zhang B, "Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection", Chest, 158, pp.e9~e13 (2020)
23. Hasan A, "A review on the cleavage priming of the spike protein on coronavirus by angiotensin-converting enzyme-2 and furin", J Biomol Struct Dyn, 39, pp.3025~3033 (2021)
24. Ogando NS, "SARS-coronavirus-2 replication in Vero E6 cells : replication kinetics, rapid adaptation and cytopathology", J Gen Virol, 101, pp.925~940 (2020)
25. Schmidt M, "The evolving faces of the SARS-CoV-2 genome", Viruses, 13, pp.1764~ (2021)
26. Harvey WT, "SARS-CoV-2 variants, spike mutations and immune escape", Nat Rev Microbiol, 19, pp.409~424 (2021)
27. Ozono S, "SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity", Nat Commun, 12, pp.848~ (2021)
28. "SARS-CoV-2 variants of concern as of 16 September 2021"[URL]
29. Li YD, "Coronavirus vaccine development : from SARS and MERS to COVID-19", J Biomed Sci, 27, pp.104~ (2020)
30. Krammer F, "SARS-CoV-2 vaccines in development", Nature, 586, pp.516~527 (2020)
31. Rizk JG, "Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic", Drug Discov Today, 26, pp.593~603 (2021)
32. Casadevall A, "The convalescent sera option for containing COVID-19", J Clin Invest, 130, pp.1545~1548 (2020)
33. Gharbharan A, "Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection", Nat Commun, 12, pp.3189~ (2021)
34. Tan CW, "A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction", Nat Biotechnol, 38, pp.1073~1078 (2020)
35. Davies NG, "Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7", Nature, 593, pp.270~274 (2021)
36. Ramatillah DL, "Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta", PLoS One, 16, pp.e0250147~ (2021)
37. Jiang S, "Neutralizing antibodies for the treatment of COVID-19", Nat Biomed Eng, 4, pp.1134~1139 (2020)
38. Pollard AJ, "A guide to vaccinology : from basic principles to new developments", Nat Rev Immunol, 21, pp.83~100 (2021)
39. Bloch EM, "Deployment of convalescent plasma for the prevention and treatment of COVID-19", J Clin Invest, 130, pp.2757~2765 (2020)
40. Barone P, "Convalescent plasma to treat coronavirus disease 2019(COVID-19) : considerations for clinical trial design", Transfusion, 60, pp.1123~1127 (2020)
41. Yuan Y, "Predictive analysis of the neutralization activity in convalescent plasmas from COVID-19 recovered patients in Zhejiang province, China, January-March, 2020", Front Cell Infect Microbiol, 11, pp.650487~ (2021)
42. Grigoryan L, "The immunology of SARS-CoV-2 infections and vaccines", Semin Immunol, 50, pp.101422~ (2020)
43. Lu Y, "Advances in neutralization assays for SARS-CoV-2", Scand J Immunol, 94, pp.224~238 (2021)
44. Chen M, "Construction and applications of SARS-CoV-2 pseudoviruses : a mini review", Int J Biol Sci, 17, pp.1574~1580 (2021)
45. Payne S, "Viruses from Understanding to Investigation", pp.37~52 (2017), Elsevier
46. Riepler L, "Comparison of four SARS-CoV-2 neutralization assays", Vaccines(Basel), 9, pp.13~ (2020)
47. Li H, "Establishment of replication-competent vesicular stomatitis virus-based recombinant viruses suitable for SARS-CoV-2 entry and neutralization assays", Emerg Microbes Infect, 9, pp.2269~2277 (2020)
48. Nie J, "Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2", Emerg Microbes Infect, 9, pp.680~686 (2020)
49. "Laboratory biosafety guidance related to the novel coronavirus (2019-nCoV)"[URL]
50. "Laboratory biosafety guidance related to coronavirus disease (COVID-19)"[URL]
51. Kaufer AM, "Laboratory biosafety measures involving SARS-CoV-2 and the classification as a Risk Group 3 biological agent", Pathology, 52, pp.790~795 (2020)
52. Wurtz N, "Culture of SARS-CoV-2 in a panel of laboratory cell lines, permissivity, and differences in growth profile", Eur J Clin Microbiol Infect Dis, 40, pp.477~484 (2021)
53. "Tropism of SARS-CoV-2 in commonly used laboratory cell lines and their proteomic landscape during infection. bioRxiv 2021" (2021)[URL]
54. Hoffmann M, "SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor", Cell, 181, pp.271~280.e8 (2020)
55. Pacciarini F, "Persistent replication of severe acute respiratory syndrome coronavirus in human tubular kidney cells selects for adaptive mutations in the membrane protein", J Virol, 82, pp.5137~5144 (2008)
56. Xie X, "An infectious cDNA clone of SARS-CoV-2", Cell Host Microbe, 27, pp.841~848.e3 (2020)
57. Harcourt J, "Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States", Emerg Infect Dis, 26, pp.1266~1273 (2020)
58. Muruato AE, "A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation", Nat Commun, 11, pp.4059~ (2020)
59. Koishi AC, "Development and evaluation of a novel high-throughput image-based fluorescent neutralization test for detection of Zika virus infection", PLoS Negl Trop Dis, 12, pp.e0006342~ (2018)
60. Shen C, "Treatment of 5 critically ill patients with COVID-19 with convalescent plasma", JAMA, 323, pp.1582~1589 (2020)
61. Duan K, "Effectiveness of convalescent plasma therapy in severe COVID-19 patients", Proc Natl Acad Sci U S A, 117, pp.9490~9496 (2020)
62. "Investigational COVID-19 convalescent plasma guidance for industry 2020"[URL]
63. Wang MY, "SARS-CoV-2 : structure, biology, and structure-based therapeutics development", Front Cell Infect Microbiol, 10, pp.587269~ (2020)
64. Li Q, "Current status on the development of pseudoviruses for enveloped viruses", Rev Med Virol, 28, pp.e1963~ (2018)
65. Sanders DA, "No false start for novel pseudotyped vectors", Curr Opin Biotechnol, 13, pp.437~442 (2002)
66. Johnson MC, "Optimized pseudotyping conditions for the SARS-COV-2 spike glycoprotein", J Virol, 94, pp.e01062~e01020 (2020)
67. Tani H, "Development and applications of VSV vectors based on cell tropism", Front Microbiol, 2, pp.272~ (2012)
68. Case JB, "Neutralizing antibody and soluble ACE2 inhibition of a replication-competent VSV-SARS-CoV-2 and a clinical isolate of SARS-CoV-2", Cell Host Microbe, 28, pp.475~485.e5 (2020)
69. Xiong HL, "Robust neutralization assay based on SARS-CoV-2 S-protein-bearing vesicular stomatitis virus(VSV)pseudovirus and ACE2-overexpressing BHK21 cells", Emerg Microbes Infect, 9, pp.2105~2113 (2020)
70. Condor Capcha JM, "Generation of SARS-CoV-2 spike pseudotyped virus for viral entry and neutralization assays : a 1-week protocol", Front Cardiovasc Med, 7, pp.618651~ (2021)
71. Whitt MA, "Generation of VSV pseudotypes using recombinant ΔG-VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines", J Virol Methods, 169, pp.365~374 (2010)
72. Almahboub SA, "Evaluation of neutralizing antibodies against highly pathogenic coronaviruses : a detailed protocol for a rapid evaluation of neutralizing antibodies using vesicular stomatitis virus pseudovirus-based assay", Front Microbiol, 11, pp.2020~ (2020)
73. Kalkeri R, "SARS-CoV-2 spike pseudoviruses : a useful tool to study virus entry and address emerging neutralization escape phenotypes", Microorganisms, 9, pp.1744~ (2021)
74. Neerukonda SN, "Establishment of a well-characterized SARS-CoV-2 lentiviral pseudovirus neutralization assay using 293T cells with stable expression of ACE2 and TMPRSS2", PLoS One, 16, pp.e0248348~ (2021)
75. Tsai WY, "A real-time and high-throughput neutralization test based on SARS-CoV-2 pseudovirus containing monomeric infrared fluorescent protein as reporter", Emerg Microbes Infect, 10, pp.894~904 (2021)
76. Xia S, "Inhibition of SARS-CoV-2(previously 2019-nCoV)infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion", Cell Res, 30, pp.343~355 (2020)
77. Liu Z, "Inefficiency of sera from mice treated with pseudotyped SARS-CoV to neutralize 2019-nCoV infection", Virol Sin, 35, pp.340~343 (2020)
78. Han DP, "Development of a safe neutralization assay for SARS-CoV and characterization of S-glycoprotein", Virology, 326, pp.140~149 (2004)
79. Bouard D, "Viral vectors : from virology to transgene expression", Br J Pharmacol, 157, pp.153~165 (2009)
80. Passariello M, "Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2", Sci Rep, 11, pp.11046~ (2021)
81. Liu Z, "RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response", Signal Transduct Target Ther, 5, pp.282~ (2020)
82. Li L, "Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China", Transfusion, 60, pp.1773~1777 (2020)
83. Petherick A, "Developing antibody tests for SARS-CoV-2", Lancet, 395, pp.1101~1102 (2020)
84. Tang YW, "The laboratory diagnosis of COVID-19 infection : current issues and challenges", J Clin Microbiol, 58, pp.e00512~e00520 (2020)
85. Okba NM, "Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease patients", Emerg Infect Dis, 26, pp.1478~1488 (2020)
86. Sil BK, "Development and performance evaluation of a rapid in-house ELISA for retrospective serosurveillance of SARS-CoV-2", PLoS One, 16, pp.e0246346~ (2021)
87. Chi X, "A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2", Science, 369, pp.650~655 (2020)
88. "WHO/BS.2020.2403 establishment of the WHO international standard and reference panel for anti-SARS-CoV-2 antibody"[URL]
89. Planas D, "Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization", Nature, 596, pp.276~280 (2021)
90. Wang B, "Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians", Lancet Reg Health West Pac, 15, pp.100276~ (2021)
91. Shen X, "Neutralization of SARS-CoV-2 variants B. 1. 429 and B. 1. 351", N Engl J Med, 384, pp.2352~2354 (2021)
92. Liu Y, "BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants", N Engl J Med, 385, pp.472~474 (2021)
93. Yeh KB, "Significance of high-containment biological laboratories performing work during the COVID-19 pandemic : biosafety level-3 and-4 labs", Front Bioeng Biotechnol, 9, pp.720315~ (2021)
94. Korber B, "Tracking changes in SARS-CoV-2 spike : evidence that D614G increases infectivity of the COVID-19 virus", Cell, 182, pp.812~827.e19 (2020)
95. Li Q, "The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity", Cell, 182, pp.1284~1294.e9 (2020)
96. Umair M, "Whole-genome sequencing of SARS-CoV-2 reveals the detection of G614 variant in Pakistan", PLoS One, 16, pp.e0248371~ (2021)

관련 논문AI추천